Title of Invention

A HEMOSTAT TO PROVIDE AND MAINTAIN EFFECTIVE HEMOSTASIS

Abstract This invention relaters to a hemostat to provide and maintain effective hemostasis, comprising an absorbable foam, an absorbable woven or knitted fabric, and thrombin and/or fibrinogen, wherein the foam comprises carboxymethyl cellulose and albumin, the ratio of carboxymethyl cellulose to the albumin ranges from about 1:8 to 8:1 by weight, wherein the absorbable woven or knitted fabric preferably comprises oxidized regenerated cellulose and may have a basis weight ranging from about 0.001 to 0.2 g/in2, and wherein the thrombin activity on the hemostat ranges from about 20 to 500 IU/cm2, and/or the fibrinogen activity ranges from about 2 to 15 mg/cm2.
Full Text FIELD OF THE INVENTION
The present invention relates to a hemostat.
BACKGROUND OF THE INVENTION
The control of bleeding, as well as sealing of air and various bodily fluids, is
essential and critical in surgical procedures to minimize blood loss, to seal tissue and
organ structures, to reduce post-surgical complications, and to shorten the duration of
the surgery in the operating room.
In an effort to provide dressings with enhanced hemostatic and tissue sealing
and adhering properties, therapeutic agents, including, but not limited to, thrombin,
fibrin and fibrinogen have been combined with dressing carriers or substrates, including
gelatin-based carriers, polysaccharide-based carriers, glycolic acid or lactic acid-based
carriers and a collagen matrix. Examples of such dressings are disclosed in USP
6,762,336, USP 6,733,774 and PCT publication WO 2004/064878 A1.
Due to its biodegradability and its bactericidal, tissue sealing, tissue repairing,
drug delivering and hemostatic properties, it is desirable to utilize cellulose that has
been oxidized to contain carboxylic acid moieties, hereinafter referred to as carboxylic-
oxidized cellulose, as a topical dressing in a variety of surgical procedures, including
neurosurgery, abdominal surgery, cardiovascular surgery, thoracic surgery, head and
neck surgery, pelvic surgery and skin and subcutaneous tissue procedures.
However, when carboxylic-oxidized cellulose is utilized in combination with
thrombin and/or fibrinogen, the acidic moieties that may be present in the cellulose
denature the activity of the thrombin and/or fibrinogen. Therefore, it is desirable to
shield the thrombin and/or fibrinogen from such acid moieties to maintain their
hemostatic activities.

SUMMARY OF THE INVENTION
The present invention is directed towards a hemostat comprising an absorbable
foam, an absorbable woven or knitted fabric, thrombin and/or fibrinogen.
DETAILED DESCRIPTION OF THE INVENTION
The hemostat described herein provides and maintains effective hemostasis
when applied to a wound requiring hemostasis. Effective hemostasis, as used herein, is
the ability to control and/or abate capillary, venous, or arteriole bleeding within an
effective time, as recognized by those skilled in the art of hemostasis. Further
indications of effective hemostasis may be provided by governmental regulatory
standards and the like.
In certain embodiments, hemostats of the present invention are effective in
providing and maintaining hemostasis in cases of severe or brisk bleeding. As used
herein, severe bleeding is meant to include those cases of bleeding where a relatively
high volume of blood is lost at a relatively high rate. Examples of severe bleeding
include, without limitation, bleeding due to arterial puncture, liver resection, blunt liver
trauma, blunt spleen trauma, aortic aneurysm, bleeding from patients with over-
anticoagulation, or bleeding from patients with coagulopathies, such as hemophilia.
The hemostat generally comprises an absorbable foam and a reinforcement
fabric. The reinforcement fabric provides a backing to which the foam may be
attached, either directly or indirectly, wherein thrombin and/or fibrinogen may be
substantially homogeneously dispersed throughout the foam and / or disposed on the
surface of the foam. The reinforcement fabric provides strength to the hemostat
sufficient to permit the user to place and manipulate the hemostat on or within a wound
or directly onto tissue of a patient requiring hemostasis, or tissue sealing and adhering.
In embodiments where the foam is directly attached to the reinforcement fabric,
fibrinogen may be substantially homogeneously dispersed throughout the foam and/or
disposed on the surface of the foam. Alternatively, thrombin may be disposed on the
surface of the foam.

In embodiments where the foam is indirectly attached to the reinforcement
fabric, fibrinogen and/or thrombin may be substantially homogeneously dispersed
throughout the foam and or disposed on the surface of the foam.
In addition to serving as a carrier for the thrombin and/or fibrinogen, the foam
also serves to shield the thrombin and/or fibrinogen from acidic moieties that may be
present in the reinforcement fabric, such as is the case where carboxylic-oxidized
cellulose is used as the reinforcement fabric.
The foam may be a biocompatible, water-soluble, or water-swellable polymer
and optionally a foaming agent/surfactant. Preferred biocompatible, water-soluble, or
water-swellable polymers used to fabricate the foam include polysaccharides. Such
polysaccharides include, without limitation, cellulose, alkyl cellulose, e.g.
methylcellulose, alkylhydroxyalkyl cellulose, hydroxyalkyl cellulose, cellulose sulfate,
salts of carboxymethyl cellulose, carboxymethyl cellulose, and carboxyethyl cellulose.
Additionally, albumin, chitin, carboxymethyl chitin, hyaluronic acid, salts of hyaluronic
acid, alginate, alginic acid, propylene glycol alginate, glycogen, dextran, dextran
sulfate, curdlan, pectin, pullulan, xanthan, chondroitin, chondroitin sulfates,
carboxymethyl dextran, carboxymethyl chitosan, chitosan, heparin, heparin sulfate,
heparan, heparan sulfate, dermatan sulfate, keratan sulfate, carrageenans, chitosan,
starch, amylose, amylopectin, poly-N-glucosamine, polymannuronic acid,
polyglucuronic acid polyguluronic acid, and derivatives of any of the above, may be
utilized. Even more preferably, biocompatible, water-soluble, or water-swellable
polymers are an alkali or alkali earth metal salts of carboxylmethyl cellulose, most
preferably sodium carboxylmethyl cellulose (CMC-Na).
The foaming agent/surfactant may be a cationic, anionic, amphoteric,
zwitterionic or nonionic surfactant, or natural or modified proteins, including but
without limitation, albumin, sodium lauryl sulfate, sodium laureth sulfate, or ammonia
lauryl sulfate. A preferred foaming agent/surfactant is albumin, and more preferably,
human serum albumin (HSA).

The reinforcement fabric is an absorbable woven or knitted fabric and comprises
oxidized polysaccharides, in particular oxidized cellulose and the neutralized
derivatives thereof. For example, the cellulose may be carboxylic-oxidized or
aldehyde-oxidized cellulose. More preferably, oxidized regenerated polysaccharides,
including but without limitation oxidized regenerated cellulose, may be used to prepare
the absorbable woven or knitted fabric. Regenerated cellulose is preferred due to its
higher degree of uniformity versus cellulose that has not been regenerated. Regenerated
cellulose and a detailed description of how to make oxidized regenerated cellulose are
set forth in USP 3,364,200, USP 5,180,398 and USP 4,626,253, the contents each of
which is hereby incorporated by reference as if set forth in its entirety.
Examples of fabrics that may be utilized as the reinforcement fabric include, but
are not limited to, Interceed® absorbable adhesion barrier, Surgicel® absorbable
hemostat, Surgicel Nu-Knit® absorbable hemostat and Surgicel® Fibrillar absorbable
hemostat (each available from Johnson & Johnson Wound Management Worldwide or
Gynecare Worldwide, each a division of Ethicon, Inc., Somerville, New Jersey).
The reinforcement fabric utilized in the present invention may be woven or
knitted, provided that the fabric possesses the physical properties necessary for use in
contemplated applications. Such fabrics, for example, are described in USP 4,626,253,
USP 5,002,551 and USP 5,007,916, the contents of which are hereby incorporated by
reference herein as if set forth in its entirety. In preferred embodiments, the
reinforcement fabric is a warp knitted tricot fabric constructed of bright rayon yarn that
is subsequently oxidized to include carboxyl or aldehyde moieties in amounts effective
to provide the fabrics with biodegradability.
In an alternative embodiment, the reinforcement fabric comprises oxidized
polysaccharide fibers in combination with fibers comprised of aliphatic polyester
polymers, copolymers, or blends thereof.

Aliphatic polyester polymers include, but are not limited to homopolymers and
copolymers of lactide (which includes lactic acid, D-, L- and meso lactide), glycolide
(including glycolic acid), epsilon-caprolactone, p-dioxanone (l,4-dioxan-2-one),
trimethylene carbonate (1, 3-dioxan-2-one), alkyl derivatives of trimethylene carbonate,
delta-valerolactone, beta-butyrolactone, gamma-butyrolactone, epsilon- decalactone,
hydroxybutyrate (repeating units), hydroxyvalerate (repeating units), l,4-dioxepan-2-
one (including its dimer 1,5, 8,12-tetraoxacyclotetradecane-7,14-dione), 1,5-dioxepan-
2-one, 6,6-dimethyl-1, 4-dioxan-2-one 2,5-diketomorpholine, pivalolactone, alpha,
alpha- diethylpropiolactone, ethylene carbonate, ethylene oxalate, 3-methyl-1,4-
dioxane-2,5-dione, 3,3-diethyl-1,4-dioxan-2,5-dione, 6,8- dioxabicycloctane-7- one and
polymer blends thereof.
The reinforcement fabric preferably comprises oxidized regenerated cellulose
and may have a basis weight ranging from about 0.001 to 0.2 g/in2, preferably in the
range of about 0.01 to 0.1 g/in2, and most preferably in the range of about 0.04 to 0.07
g/in2.
In preparing the hemostats, a foam slurry may be prepared from, for example,
CMC-Na and HSA, and then spread on the surface of, for example, an oxidized
regenerated cellulose fabric. The ratio of the water-soluble or water-swellable polymer
to the foaming agent may range from about 1:8 to 8:1 by weight, and preferably from
about 2:1 to 1:2 by weight. The foam slurry is then dried either by lyophilization or in
an oven at elevated temperature to form a solid foam substrate. The foam substrate
may be treated with a chemical cross-1inking agent such as glutaraldehyde for increased
strength or may be partly cross-1inked by heating. The density of the hemostat may be
from about 5 to 20 mg/cm3.
The thrombin and/or fibrinogen may be animal derived, preferably human, or
may be recombinant. The thrombin activity on the hemostat may be in the range of
about 20 to 500 IU/cm2, preferably about 20 to 200 IU/cm2, and most preferably about
50 to 200 IU/cm2. The fibrinogen activity on the hemostat may be in the range of about

2 to 15 mg/cm2, preferably about 3 to 10 mg/cm2, and most preferably about 4 to 7
mg/cm2.
Thrombin powders may be prepared by lyophilization of thrombin solutions.
Fibrinogen may be prepared by lyophilizaton of solutions containing fibrinogen, such as
those described in USP 6,121,232 and PCT Application Publication No. WO
02/095019. Dry powders of fibrinogen and thrombin suspended in an organic solvent
such as PF5060 or HFE 7000—7300 series are then sprayed onto the surface of the
foam. Alternatively, the thrombin and/or fibrinogen may be incorporated into the foam
during the foam production.
In an alternate embodiment, the hemostat may comprise a first foam having
incorporated thereon or therein a first therapeutic agent, e.g., fibrinogen, and a second
foam separate (unattached) from the first foam that may have upon or incorporated
therein powders of a second therapeutic agent, e.g. thrombin.
In an alternative embodiment, a hemostat may comprise a reinforcement fabric
having a first foam adjacent thereto and second foam on the other side of the first foam.
Fibrinogen may be incorporated into or onto the first foam. While either thrombin or
fibrinogen may be incorporated into or onto the second foam, thrombin is preferred. In
such an embodiment, the foam slurries used to prepare the first and second foams are
selected such that the second foam is less dense than the first foam so that it liquefies or
melts quickly after coming into contact with blood at the wound site to start the clotting
process. The second foam contacts the bleeding site first, then the combined
reinforcing layer and first foam keeps the clot from being washed away by the blood
flow.
In another alternative embodiment, the hemostat may comprise a foam having
incorporated thereon or therein thrombin and/or fibrinogen, a nonwoven, and a
reinforcement fabric wherein the foam is indirectly attached to the reinforcement fabric
via the nonwoven. The nonwoven may be comprised of aliphatic polyester fibers such
as those described herein.

The hemostat comprising a foam having incorporated thereon or therein
thrombin and/or fibrinogen, a nonwoven, and a reinforcement fabric wherein the foam
is indirectly attached to the reinforcement fabric via the nonwoven may be prepared in
the following manner. A nonwoven comprising a copolymer of lactide and glycolide is
needlepunched to the oxidized regenerated cellulose reinforcement fabric. An aqueous
solution of about 0.2 to about 1.5% hyaluronic acid and thrombin is prepared. The
aqueous solution is then spread upon the surface of the nonwoven such that it partially
penetrates the nonwoven. The solution layer is foamed by lyophilization.
The nonwoven is made by processes other than spinning, weaving or knitting.
For example, the nonwoven may be prepared from yarn, scrims, netting, fibers or
filaments that have been made by processes that include spinning, weaving or knitting.
The yarn, scrims, netting fibers and/or filaments are crimped to enhance entanglement
with each other. Such crimped yarn, scrims, netting fibers and/or filaments may then be
cut into staple that is long enough to entangle. The staple may be carded to create
nonwoven bats, which may be then needlepunched or calendared. Additionally, the
staple may be kinked or piled. Other methods known for the production of nonwovens
may be utilized and include such processes as air laying, wet forming and stitch
bonding.
The hemostat may optionally include without limitation, procoagulant enzymes,
proteins and peptides, may be naturally occurring, recombinant, or synthetic, and may
be selected from the group consisting of prothrombin, fibrin, fibronectin, heparinase,
Factor X/Xa, Factor VII/VIIa, Factor IX/IXa, Factor XI/XIa, Factor XII/XIIa, tissue
factor, batroxobin, ancrod, ecarin, von Willebrand Factor, collagen, elastin, albumin,
gelatin, platelet surface glycoproteins, vasopressin and vasopressin analogs,
epinephrine, selectin, procoagulant venom, plasminogen activator inhibitor, platelet
activating agents, synthetic peptides having hemostatic activity, derivatives of the above
and any combination thereof.
The hemostat described herein may also be used as an adjunct to primary wound
closure devices, such as arterial closure devices, staples, and sutures, to seal potential

leaks of gasses, liquids, or solids as well as to provide hemostasis. For example, the
hemostat may be utilized to seal air from tissue or fluids from organs and tissues,
including but not limited to, bile, lymph, cerebrospinal fluids, gastrointestinal fluids,
interstitial fluids and urine.
The hemostat described herein has additional medical applications and may be
used for a variety of clinical functions, including but not limited to tissue
reienforcement and buttressing, i.e., for gastrointestinal or vascular anastomoses,
approximation, i.e., to connect anastomoses that are difficult to perform (i.e. under
tension), and tension releasing. The hemostat may additionally promote and possibly
enhance the natural tissue healing process in all the above events. This hemostat can be
used internally in many types of surgery, including, but not limited to, cardiovascular,
peripheral-vascular, cardio-thoracic, gynecological, neuro- and general surgery. The
hemostat may also be used to attach medical devices (e.g. meshes, clips and films) to
tissues, tissue to tissue, or medical device to medical device.
Example 1. Lyophilized CMC-Na/ HSA foam with ORC fabric
In a mixing bowl were added 190 mL of a 2% solution of sodium carboxy
methylcellulose (CMC-Na) (Aqualon, catalog No. 7M8SFPH) and 10 mL of a 20%
solution of human serum albumin (HSA) (ALBUTEIN™, Alpha Therapeutic
Corporation). The mixture was whipped mechanically to generate a foamed slurry.
The foamed slurry was transferred to a rectangular frame having a piece of knitted
carboxylic-oxidized regenerated cellulose fabric, available from Ethicon, Inc. under the
tradename Interceed®, disposed at the bottom. The foamed slurry was then spread
evenly across the whole frame to yield a thickness of about 3 mm. The foamed slurry
was then lyophilized to remove solvent, thus yielding a solid CMC-Na/HSA foam
adjacent and attached to the ORC fabric.
Example 2. Heat-treated CMC-Na/ HSA foam with ORC fabric
In a mixing bowl were added 190 mL of 2% solution of sodium carboxy
methylcellulose (CMC-Na) (Aqualon, catalog No. 7M8SFPH) and 10 mL of 20%
solution of human serum albumin (HSA) (ALBUTEIN™, Alpha Therapeutic

Corporation). The mixture was whipped mechanically to generate a foamed slurry.
The foamed slurry was transferred to a rectangular frame having a piece of carboxylic-
oxidized regenerated cellulose fabric, available from Ethicon, Inc. under the tradename
Interceed®, at the bottom. The foamed slurry was then spread evenly across the whole
frame to yield a thickness of about 3 mm. The foamed slurry was then heated in an
oven at 65°C for an hour to remove solvent and thus yielded a solid CMC-Na/HSA
foam adjacent and attached to the ORC fabric.
Example 3. Reinforced Foams with active clotting factors
Hemostatic agents were applied to the constructs prepared in Examples 1 and 2
as below. The constructs were cut into 3" x 4" pieces. Lyophilized thrombin and
Biological Active Components 2 (BAC-2) containing fibrinogen were ground to
powder separately. The thrombin powder and the BAC-2 powder were passed through
a 45-micrometer sieve. The two powders were weighed to provide a final fibrinogen
concentration of 6 mg/cm2, 7 mg/cm2 or 8 mg/cm2, and a thrombin activity of 50
IU/cm2. The powders were then mixed and suspended in a per-fluorinated solvent HFE
7000 in a flask. The suspension then was sprayed onto the various constructs and then
dried under nitrogen at room temperature for 1 hour.
Example 4. Hemostasis test in a swine spleen linear incision model
Linear incisions (1.5 cm long and 0.3 cm deep) were made on a swine spleen.
After spraying the wound with 0.9% saline solution, various test materials from
Example 3 were applied to the wounds. Tamponade was applied for 30 seconds
followed by a 30-second observation. When hemostasis was not achieved, additional
tamponade was applied to stop the bleeding. A piece of surgical gauze and a
commercial product Tachocomb® surgical patch (commercially available from
Nycomed Pharma GmbH) were used as controls. Table 1 lists the experimental results.



Example 5. CMC-Na/HSA foam with thrombin
In a mixing bowl were added 190 mL of a 2% solution of sodium carboxy
methylcellulose (CMC-Na) (Aqualon, catalog No. 7M8SFPH) and 10 mL of a 20%
solution of human serum albumin (HSA) (ALBUTEIN™, Alpha Therapeutic
Corporation). The mixture was whipped mechanically to generate a foamed slurry. A
portion of the foamed slurry was transferred to a glass beaker. Thrombin powder was
folded into the foamed slurry to yield an estimated activity of 1,000 IU/cm3. The final
mixture was lyophilized in aluminum weighing dishes with a height of 0.5 cm to form a
solid foam comprising the thrombin dispersed therethrough.
Example 6. CMC-Na/HSA foam with fibrinogen
In a mixing bowl were added 190 mL of 2% solution of sodium carboxy
methylcellulose (CMC-Na) (Aqualon, catalog No. 7M8SFPH) and 10 mL of 20%
solution of human serum albumin (HSA) (ALBUTEIN™, Alpha Therapeutic
Corporation). The mixture was whipped mechanically to generate a foamed slurry. A
portion of the foamed slurry was transferred to a glass beaker. Five grams of fibrinogen
powder was folded into the foam. The final mixture was placed in an aluminum
weighing dish with a height of 0.5 cm and a having a piece of ORC fabric at the
bottom. The foamed slurry then was lyophilized to form a solid foam comprising the
fibrinogen dispersed therethrough.

Example 7. Hemostasis test with CMC-Na/HSA/Thrombin foam and CMC-
Na/HSA/Fibrinogen foam
A severe bleeding wound was made on a swine liver. The defect was created by
making a triangular cut with a surgical scalpel. Each side measured about 1 inch and
the depth measured 5mm. After the triangular liver tissue was removed, CMC-
Na/HSA/Thrombin foam (1" x 1") was quickly applied to the wound. A piece of CMC-
Na/HSA/Fibrinogen foam was then applied on top of the thrombin foam followed by
manual compression. Hemostasis was achieved in 2 minutes.

WE CLAIM
1. A hemostat to provide and maintain effective hemostasis, comprising an
absorbable foam, an absorbable woven or knitted fabric, and thrombin and/or
fibrinogen, wherein the foam comprises carboxymethyl cellulose and albumin,
the ratio of carboxymethyl cellulose to the albumin ranges from about 1:8 to
8:1 by weight, wherein the absorbable woven or knitted fabric preferably
comprises oxidized regenerated cellulose and may have a basis weight
ranging from about 0.001 to 0.2 g/in2, and wherein the thrombin activity on
the hemostat ranges from about 20 to 500 IU/cm2, and/or the fibrinogen
activity ranges from about 2 to 15 mg/cm2.
2. The hemostat as claimed in claim 1, wherein the foam comprises one or more
polymers selected from the group consisting of polysaccharides, albumin,
chitin, carboxymethyl chitin, hyaluronic acid, salts of hyaluronic acid, alginate,
alginic acid, propylene glycol alginate, glycogen, dextran, dextran sulfate,
curdlan, pectin, pullulan, xanthan, chondroitin, chondroitin sulfates,
carboxymethyl dextran, carboxymethyl chitosan, chitosan, heparin, heparin
sulfate, heparan, heparan sulfate, dermatan sulfate, keratin sulfate,
carrageenans, chitosan, starch, amylose, amylopectin, poly-N-glucosamine,
polymannuronic acid, polyglucuronic acid polyguluronic acid, and derivatives
of any of the above.
3. The hemostat as claimed in claim 2, wherein the foam comprises a
polysaccharide selected from the group consisting of methylcellulose,
alkylhydroxyalkyl cellulose, hydroxyalkyl cellulose, cellulose sulfate, salts of
carboxymethyl cellulose, carboxymethyl cellulose, carboxyethyl cellulose.

4. The hemostat as claimed in claim 1, wherein the absorbable woven or knitted
fabric comprises oxidized regenerated cellulose, and the thrombin and/or
fibrinogen are incorporated into or sprayed onto the foam.
5. The hemostat as claimed in claim 2, wherein the foam comprises hyaluronic
acid or salts thereof and thrombin and/or fibrinogen is incorporated into the
foam.
6. The hemostat as claimed in any one of claims 1 to 5, wherein the hemostat is
sterilized.
7. The hemostat as claimed in claim 6, wherein the hemostat is sterilized by
electron beam sterilization to a sterility assurance level of 10-6 with an
absorbed dose from 4 to 25 kGy.


ABSTRACT

TITLE : "A HEMOSTAT TO PROVIDE AND MAINTAIN EFFECTIVE
HEMOSTASIS"
This invention relaters to a hemostat to provide and maintain effective
hemostasis, comprising an absorbable foam, an absorbable woven or knitted
fabric, and thrombin and/or fibrinogen, wherein the foam comprises
carboxymethyl cellulose and albumin, the ratio of carboxymethyl cellulose to the
albumin ranges from about 1:8 to 8:1 by weight, wherein the absorbable woven
or knitted fabric preferably comprises oxidized regenerated cellulose and may
have a basis weight ranging from about 0.001 to 0.2 g/in2, and wherein the
thrombin activity on the hemostat ranges from about 20 to 500 IU/cm2, and/or
the fibrinogen activity ranges from about 2 to 15 mg/cm2.

Documents:

01338-kolnp-2007-abstract.pdf

01338-kolnp-2007-claims1.0.pdf

01338-kolnp-2007-claims1.1.pdf

01338-kolnp-2007-correspondence others 1.1.pdf

01338-kolnp-2007-correspondence others.pdf

01338-kolnp-2007-description complete.pdf

01338-kolnp-2007-form 1.pdf

01338-kolnp-2007-form 2.pdf

01338-kolnp-2007-form 3.pdf

01338-kolnp-2007-form 5.pdf

01338-kolnp-2007-gpa.pdf

01338-kolnp-2007-international publication.pdf

01338-kolnp-2007-international search report.pdf

1338-KOLNP-2007-(27-01-2012)-ABSTRACT.pdf

1338-KOLNP-2007-(27-01-2012)-AMANDED CLAIMS.pdf

1338-KOLNP-2007-(27-01-2012)-CORRESPONDENCE.pdf

1338-KOLNP-2007-(27-01-2012)-DESCRIPTION (COMPLETE).pdf

1338-KOLNP-2007-(27-01-2012)-FORM 1.pdf

1338-KOLNP-2007-(27-01-2012)-FORM 2.pdf

1338-KOLNP-2007-(27-01-2012)-PA.pdf

1338-KOLnp-2007-ABSTRACT 1.1.pdf

1338-KOLnp-2007-AMANDED CLAIMS.pdf

1338-KOLNP-2007-ASSIGNMENT.pdf

1338-KOLNP-2007-CORRESPONDENCE 1.1.pdf

1338-KOLNP-2007-CORRESPONDENCE.pdf

1338-KOLnp-2007-DESCRIPTION (COMPLETE) 1.1.pdf

1338-KOLnp-2007-EXAMINATION REPORT REPLY RECIEVED.pdf

1338-KOLNP-2007-EXAMINATION REPORT.pdf

1338-KOLnp-2007-FORM 1-1.1.pdf

1338-KOLNP-2007-FORM 18 1.1.pdf

1338-kolnp-2007-form 18.pdf

1338-KOLnp-2007-FORM 2-1.1.pdf

1338-KOLNP-2007-FORM 26.pdf

1338-KOLNP-2007-FORM 3 1.1.pdf

1338-KOLnp-2007-FORM 3-1.1.pdf

1338-KOLNP-2007-FORM 5.pdf

1338-KOLNP-2007-GRANTED-ABSTRACT.pdf

1338-KOLNP-2007-GRANTED-CLAIMS.pdf

1338-KOLNP-2007-GRANTED-DESCRIPTION (COMPLETE).pdf

1338-KOLNP-2007-GRANTED-FORM 1.pdf

1338-KOLNP-2007-GRANTED-FORM 2.pdf

1338-KOLNP-2007-GRANTED-SPECIFICATION.pdf

1338-KOLNP-2007-INTENATIONAL PUBLICATION.pdf

1338-KOLnp-2007-OTHERS 1.1.pdf

1338-KOLNP-2007-PETITION UNDER RULE 137.pdf

1338-KOLNP-2007-PETITION UNDER RULR 137-1.1.pdf

1338-KOLNP-2007-REPLY TO EXAMINATION REPORT.pdf


Patent Number 253520
Indian Patent Application Number 1338/KOLNP/2007
PG Journal Number 30/2012
Publication Date 27-Jul-2012
Grant Date 26-Jul-2012
Date of Filing 17-Apr-2007
Name of Patentee OMRIX BIOPHARMACEUTICAL, INC
Applicant Address CHAUSSE DE WATERLOO, 200, B-1640 RHODE-ST-GENESE
Inventors:
# Inventor's Name Inventor's Address
1 ZHANG, GUANGHUI 4 MILLERS GROVE ROAD, BELLE MEAD, NJ 08502
2 PETERS, ROBIN 24 KERSHAW COURT, BRIDGEWATER, NJ 08807
3 MARTINS, SONIA 222 AMITY STREET, ELIZABETH, NJ 07202
PCT International Classification Number A61L 15/32
PCT International Application Number PCT/US2005/037408
PCT International Filing date 2005-10-17
PCT Conventions:
# PCT Application Number Date of Convention Priority Country
1 60/620,539 2004-10-20 U.S.A.
2 60/696,258 2005-07-01 U.S.A.